-+ 0.00%
-+ 0.00%
-+ 0.00%

Quantum BioPharma plans debt conversion at conversion price of CAD 4 per share

PUBT·09/17/2026 19:13:36
Listen to the news
Quantum BioPharma plans debt conversion at conversion price of CAD 4 per share
  • Quantum BioPharma outlined terms for secured convertible debentures in a planned private placement, including quarterly cash interest starting June 30, 2026.
  • Debentures carry 1.25% monthly interest, mature 24 months from issuance, with principal or accrued interest convertible at CAD 4 per share.
  • Separately, it plans a debt settlement with creditors through share issuance at a deemed price equal to the CAD 4 conversion price.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quantum Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-26-004098), on September 17, 2026, and is solely responsible for the information contained therein.